Edwards Cardioband Tricuspid - Recorded case from Heart Center Bonn

Georg Nickenig
Heart Center
Universitätsklinikum Bonn
Germany
Potential conflicts of interest

Speaker's name: Georg Nickenig

I, Georg Nickenig, have or had a financial interest/arrangement or affiliation with the organization(s) listed

<table>
<thead>
<tr>
<th>Affiliation/Financial Relationship</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Honoraria for lectures or advisory boards</td>
<td>Abbott, AGA, AstraZeneca, Bayer, Berlin Chemie, Biosensus, Biotronic, BMS, Boehringer Ingelheim, Daiichi Sankyo, Edwards, Medtronic, Mitratech, Novartis, Pfizer, Sanofi Aventis, St. Jude, Valtec</td>
</tr>
<tr>
<td>2. Participation in clinical trials</td>
<td>Abbott, AGA, AstraZeneca, Bayer, Berlin Chemie, Biosensus, Biotronic, BMS, Boehringer Ingelheim, Daiichi Sankyo, Edwards, Medtronic, Mitratech, Novartis, Pfizer, Sanofi Aventis, St. Jude, Valtec</td>
</tr>
<tr>
<td>3. Research funding</td>
<td>DFG, BMBF, EU, Abbott, AGA, AstraZeneca, Bayer, Berlin Chemie, Biosensus, Biotronic, BMS, Boehringer Ingelheim, Daiichi Sankyo, Edwards, Medtronic, Mitratech, Novartis, Pfizer, Sanofi Aventis, St. Jude, Valtec</td>
</tr>
</tbody>
</table>
Edwards Cardioband Transcatheter Tricuspid Repair System

- Transfemoral tricuspid annular reduction
  - Dedicated technology to treat tricuspid regurgitation
  - Same concept and similar implant technique used with Edwards Cardioband mitral repair system

- Short learning curve for EW Cardioband mitral system users

This version not approved in any country
Edwards Cardioband Tricuspid System Procedure: Step-by-Step

1. Transfemoral Approach
2. System Insertion
3. Implant Deployment
4. Implant Size Adjustment

CAUTION: Exclusively for clinical investigations. To be used by qualified investigators only. Not available for commercial use until validly CE marked
TR before and after Cardioband

Pre-procedure: Massive TR

Post-procedure: Trace-mild TR
Conclusions

- Use of Edwards Cardioband System for tricuspid regurgitation is feasible
- Significant annular reduction
- Substantially reduced TR at 30 days